On July 28, 2025, China Medical System Holdings Ltd. announced that the National Medical Products Administration of China (NMPA) has accepted the New Drug Application for ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets). This improved new drug is indicated for the treatment of mild-to-moderate dementia of the Alzheimer's type in adults. Previously approved by the U.S. Food and Drug Administration (FDA) in July 2024, ZUNVEYL acts as a new generation acetylcholinesterase inhibitor, helping to increase acetylcholine levels in the central nervous system and improve cognitive functions. This development marks a significant step towards addressing cognitive impairment in Alzheimer's patients in China. The announcement highlighted that this acceptance is solely related to China Medical System Holdings Ltd., without mention of any grant or funding involving multiple organizations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.